Thursday, August 08, 2019 6:16:00 AM
________________________________________________________________________________________________________________
INDUSTRY CONSORTIUM FOR ERP BIOMARKERS LAUNCHED:
Benefit of the Consortium:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150172628
"Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects" - Consortium sponsors.
https://clinicaltrials.gov/ct2/show/NCT04025502
Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488
About erpbiomarkers.org:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147668300
Purpose of the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169319
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169571
Antipsychotics, also known as neuroleptics, are a class of drugs used to treat psychiatric disorders.. (from kevli33 )
https://youtu.be/nKkIh1B2Js8
Schizophrenia trial Announced:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150013370
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150015845
Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488
Daniel C. Javitt, MD | Columbia University Department of Psychiatry
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147699581
Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches.
(link from georgejjl)
https://www.ncbi.nlm.nih.gov/pubmed/28890198
see also:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461562/
Larry Ereshefsky has been working on Schizophrenia for a long time:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147697607
ERP - Cognision and Anavex partnership
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147690818
Cognision 510K Certification:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147839850
Notes on the above from TempePhil:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179
2015 mention of ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307
Biostockclub holds forth on the Consortium and the history of Big Pharma:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147996854
Lima4918- opinions about the Alzheimer's Consortium:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149153359
see also NeuroNetrix below:
________________________________________________________________________________________________________________
NEURONETRIX:
Neuonetrix partnership
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166429
Anavex CHOSE Neuronetrix for its A2-73 P2a trial for Alzh. (see Nov. 7,2014 press release).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150174092
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166593
Why does Marco Cecchi (CSO of Neuronetrix) show up as the inventor in this world patent application for 2-73?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147174749
Origins of 3-71:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148063609
________________________________________________________________________________________________________________
ARIANA:
Ariana background info from Kevli 33
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147023718
Corrected link from above:
https://www.anavex.com/anavex-life-sciences-and-ariana-pharma-collaborate-to-accelerate-timelines-and-improve-efficiency-of-alzheimers-and-parkinsons-clinical-development-programs/ chi
Anavex and Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/
Another article by Ariana Pharma on their website, this time highlighting the CTAD presentation:
http://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/
________________________________________________________________________________________________________________
ALZHEIMER PRECISION MEDICINE INITIATIVE:
It’s interesting that Hampel says at the end of this video. “That is why the Alzheimer Precision Medicine Initiative and Anavex is collaborating on this project.” This was most likely pointed out before but worth a second visit.
And also why Hampel uses WE when discussing the trial. How much collaboration was there?
(comment and repost from Jonjones325 on 7/7/19)
The Alzheimer Precision Medicine Initiative
Led by Harald Hampel
https://www.apmiscience.com
Cbdpotential on systems and reference to a 2017 paper by Harald Hampel:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149737160
Harald Hampel: “That is why the Alzheimer Precision Medicine Initiative and Anavex is collaborating on this project.”
A former member of the Anavex Scientific Advisory Board and an internationally recognized expert on Alzheimer’s and related neurodegenerative diseases, Dr. Hampel is Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC) in Paris, the leading university in science, technology and medicine in France. The AXA-UPMC Chair is hosted within the highly specialized Institute for Memory and Alzheimer’s Disease (IM2A), a reference center for Alzheimer’s and other neurodegenerative diseases, and affiliated with a leading neuroscience institution, the Brain and Spine Institute (ICM), as well as the Department of Neurology at the Pitié-Salpétrière University Hospital. He has conducted more than 50 clinical trials over the past 20 years and has developed international programs focused on Alzheimer’s therapy, diagnosis and the development of biological and imaging biomarkers, including his current work as AXA-UPMC Chair, which aims to improve early detection at the preclinical ‘silent stage’ before the onset of any clinical signs and symptoms. After a post-doctoral fellowship focused on structural and functional neuroimaging of the healthy aging and Alzheimer’s disease brain at the NIH/NIA Laboratory of Neurosciences in Bethesda, MD, Dr. Hampel became founding director of the Alzheimer Memorial Center and Professor of Psychiatry at the University of Munich. In 2006, he was appointed as a Professor and Chair of Psychiatry at Trinity College, University of Dublin, Ireland. During this time, he was a leading Principal Investigator at the Trinity College Institute of Neuroscience (TCIN). In 2010, Dr. Hampel was appointed as Professor, Chair and Head of Department of Psychiatry and Co-Director of the Brain Imaging Center (BIC) at the University of Frankfurt. Dr. Hampel has published more than 500 peer-reviewed research papers, 80 book chapters and eight books, many in world-leading scientific journals, such as the New England Journal of Medicine, JAMA, The Lancet, The Lancet Neurology, Nature Genetics, Nature Reviews Drug Discovery and Nature Reviews Neurology. He has won numerous awards for his scientific work on healthy and diseased brains as well as biomarker and therapy discovery in Alzheimer’s. Additionally, Dr. Hampel has been a reviewer for leading international scientific journals and funding agencies in the US, Canada and Europe and is Senior Associate Editor of the leading international Alzheimer’s journal Alzheimer’s & Dementia, the journal of the Alzheimer’s Association.
Research Gate intro:
https://www.researchgate.net/profile/Harald_Hampel
Hampel's August 2018 statement on the action of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145787370
HH twitter:
https://twitter.com/harald_hampel#
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147429124
Revolution of Alzheimer Precision Neurology: Passageway of Systems Biology and Neurophysiology
Harald Hampel primary author, posted by nidan7500
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008221/#!po=0.337838
Harald Hampel tweets this paper (from kevli33):
Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450260/
https://twitter.com/harald_hampel/status/1118495219895476226
Hampel on precision Medicine and Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148302986
Hampel APMI bio link:
https://www.apmiscience.com/working-group-1
Dr. Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study 10/18, Videos:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148601340
Hampel and precision medicine:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138458647
Eisai names Harald Hampel VP Global Medical Affairs
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team
More on Eisai's Alzheimer's moves.... (from Talon38)
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team
https://www.biospace.com/article/eisai-continues-alzheimer-s-research-adds-2-alzheimer-s-pros-as-execs
"Our paper on plasma amyloid beat 40/42 ration predicts cerebral amyloidosis in asymptomatic at risk individuals for AD has been published in Alzheimer's & Dementia"(from kevli33 quoting Harald Hampel tweet)
https://goo.gl/scholar/JZH7Zw
_________________________________________________________________________________________
COGNISION and NEURONETRIX:
Neuonetrix partnership
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166429
Anavex CHOSE Neuronetrix for its A2-73 P2a trial for Alzh. (see Nov. 7,2014 press release).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150174092
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166593
Why does Marco Cecchi (CSO of Neuronetrix) show up as the inventor in this world patent application for 2-73?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147174749
4/3/19 - New position paper from FDA on AI.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271
Summary of the Cecchi ERP patent application...as paid for by Anavex(applicant).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179
Tool suite used in the Cognision patent (thanks Nidan7500):
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
https://www.advancedbrainmonitoring.com/
Link to the patent application
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147781853
New EEG techniques for Alzheimer's and other CNS disease under development, including AI:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145774113
A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
P300 amplitude recovers to healthy levels over 53 weeks in the P2a and extension
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146074463
Cognision protocol for TBI (from georgejjl)
http://www.cognision.com/wp-content/uploads/2018/09/ERP-for-Diagnosis-and-Prognosis-of-Traumatic-Brain-Injury-9-18.pdf
Cognision on diagnostic process, FDA approval:
http://www.cognision.com/wp-content/uploads/2017/11/Clinical-Study-FDA-Approval.pdf
2015 mention of ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307
Past posts on Cognision and Erp:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145755014
Possible approval based on sleep, with ERP/EEG taken as suporting biomarker evidence
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148919365
Cognision and ERP/EEG tracking in trials - is this why trials are adding sites slowly?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148909354
________________________________________________________________________________________________________________
McGill University:
Canadian University that does a lot of Anavex preclinical research.
https://www.mcgill.ca/neuro/
McGill, Merck and Canada's CDRD join in researh effort 2017
https://www.mcgill.ca/neuro/channels/news/health-science-leaders-join-forces-accelerate-development-treatments-neurological-diseases-267104
________________________________________________________________________________________________________________
Manufacturing Partners:
Theory on Anavex Manufacturing partner..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148205960
________________________________________________________________________________________________________________
MAYBE MERCK ????:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149038386
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148209671
Merck Canada funding research on 2-73 and 3-71 and possibility of a combo:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148210694
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148210824
________________________________________________________________________________________________________________
Lund University:
Dr. Angela Cenci-Nilsson and Dr. Veronica Francardo's Lund University:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342353
Dr. M. Angela Cenci Nilsson resulting study from the 2015 research grant for Parkinson's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148339012
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342120
PROFILE
http://www.academia-net.org/profil/prof-dr-m-angela-cenci-nilsson/1488381
Veronica Francardo
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342376
Francardo May 2018 statement on effect of 2-73 in Parkinson's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134044839
Anavex PR's from the Lund preclinical research on Parkinson's by Cenci-Nilsson and Francardo.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148343391
________________________________________________________________________________________________________________
Manufacturing Partners & Potential Partners:
Theory on Anavex Manufacturing partner..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148205960
More on Eisai's Alzheimer's moves.... (from Talon38)
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team
https://www.biospace.com/article/eisai-continues-alzheimer-s-research-adds-2-alzheimer-s-pros-as-execs
Recent AVXL News
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM